FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Back

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Physiology

Drug Interactions

Concepts & Ideas

Procedures

Living Beings

HIV-1

Co-author Network

Publications

TOP 3
Kay Seden; Mairin Ryan; David Back; Pauline Byakika-Kibwika; Saye H Khoo; Mohammed Lamorde; Concepta Merry
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.
Aylin Yilmaz; Laura Dickinson; Victoria Watson; David Back
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Akil Jackson; Saye Khoo; Graeme Moyle; Jessica Taylor; George Abongomera; David Back; Laura Dickinson; Brian Gazzard; Keerti Gedela; Marta Boffito
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Back (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Kay Seden; Mairin Ryan; David Back; Pauline Byakika-Kibwika; Saye H Khoo; Mohammed Lamorde; Concepta Merry
Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting.
The Journal of antimicrobial chemotherapy 2013;68(1):1-3.
2012: Aylin Yilmaz; Laura Dickinson; Victoria Watson; David Back
Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
Antimicrobial agents and chemotherapy 2012;56(9):4583-5.
2012: Akil Jackson; Saye Khoo; Graeme Moyle; Jessica Taylor; George Abongomera; David Back; Laura Dickinson; Brian Gazzard; Keerti Gedela; Marta Boffito
Pharmacokinetics of abacavir and its anabolite carbovir triphosphate without and with darunavir/ritonavir or raltegravir in HIV-infected subjects.
Antiviral therapy 2012;17(1):19-24.
2011: Andrew Hill; Saye Khoo; Marta Boffito; David Back
Should we switch to a 50-mg boosting dose of ritonavir for selected protease inhibitors?
Journal of acquired immune deficiency syndromes (1999) 2011;58(5):e137-8.
2011: Akil Jackson; Saye Khoo; Neill Liptrott; Victoria Watson; Deidre Egan; Brian Gazzard; Keerti Gedela; Chris Higgs; Riaz Abbas; David Back; Marta Boffito
Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2011;58(5):450-7.
2011: Marta Boffito; Brian Gazzard; Christopher Higgs; Akil Jackson; Saye Khoo; Alieu Amara; David Back; Natalia Seymour; Graeme Moyle
Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation.
Antimicrobial agents and chemotherapy 2011;55(9):4218-23.
2011: Laura Dickinson; Marta Boffito; David Back; Laura Else; Nils von Hentig; Geraint Davies; Saye Khoo; Anton Pozniak; Graeme Moyle; Leon Aarons
Sequential population pharmacokinetic modeling of lopinavir and ritonavir in healthy volunteers and assessment of different dosing strategies.
Antimicrobial agents and chemotherapy 2011;55(6):2775-82.
2011: Akil Jackson; Antonio D'Avolio; Victoria Watson; Stefano Bonora; David Back; Jessica Taylor; Kostantinos Armenis; Brian Gazzard; Graeme Moyle; Marta Boffito
Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers.
The Journal of antimicrobial chemotherapy 2011;66(4):885-9.
2011: Akil Jackson; Andrew Hill; Rebekah Puls; Laura Else; Janaki Amin; David Back; Enmoore Lin; Saye Khoo; Sean Emery; Roland Morley; Brian Gazzard; Marta Boffito
Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.
The Journal of antimicrobial chemotherapy 2011;66(3):635-40.
2010: Kay Seden; Laura Dickinson; Saye Khoo; David Back
Grapefruit-drug interactions.
Drugs 2010;70(18):2373-407.
2010: Laura Else; Victoria Watson; John F Tjia; Andrew Hughes; Marco Siccardi; Saye Khoo; David Back
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(19):1455-65.
2010: Kay Seden; David Back; Saye Khoo
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
The Journal of antimicrobial chemotherapy 2010;65(6):1079-85.
2010: Philip Martin; Robert Riley; Paul Thompson; Dominic Williams; David Back; Andrew Owen
Effect of prototypical inducers on ligand activated nuclear receptor regulated drug disposition genes in rodent hepatic and intestinal cells.
Acta pharmacologica Sinica 2010;31(1):51-65.
2009: Marta Boffito; Akil Jackson; Mohammed Lamorde; David Back; Victoria Watson; Jessica Taylor; Laura Waters; David Asboe; Brian Gazzard; Anton Pozniak
Pharmacokinetics and safety of etravirine administered once or twice daily after 2 weeks treatment with efavirenz in healthy volunteers.
Journal of acquired immune deficiency syndromes (1999) 2009;52(2):222-7.
2009: Wai San Kwan; Omar Janneh; Ruben Hartkoorn; Becky Chandler; Saye Khoo; David Back; Andrew Owen
Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.
British journal of clinical pharmacology 2009;68(3):375-80.
2008: Laura Dickinson; Saye Khoo; David Back
Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.
Current opinion in HIV and AIDS 2008;3(3):296-305.
2008: Marta Boffito; Laura Else; David Back; Jessica Taylor; Saye Khoo; Marta Sousa; Anton Pozniak; Brian Gazzard; Graeme Moyle
Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Antiviral therapy 2008;13(7):901-7.
2008: David Back; Vanitha Sekar; Richard Hoetelmans
Darunavir: pharmacokinetics and drug interactions.
Antiviral therapy 2008;13(1):1-13.
2007: Stephen Taylor; Marta Boffito; Saye Khoo; Erasmus Smit; David Back
Stopping antiretroviral therapy.
AIDS (London, England) 2007;21(13):1673-82.
2007: Laura Dickinson; David Back; Anton Pozniak; Saye Khoo; Marta Boffito
Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals.
Therapeutic drug monitoring 2007;29(3):361-7.
2007: Lauro J Waters; Graeme Moyle; Stefano Bonora; Antonio D'Avolio; Laura Else; Sundhiya Mandalia; Anton Pozniak; Mark Nelson; Brian Gazzard; David Back; Marta Boffito
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Antiviral therapy 2007;12(5):825-30.
2006: Jennifer Ford; Marta Boffito; Desmond Maitland; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
The Journal of antimicrobial chemotherapy 2006;58(5):1009-16.
2006: Samantha L Hider; A Owen; Ruben C Hartkoorn; Saye Khoo; David Back; Alan J Silman; Ian N Bruce
Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
Annals of the rheumatic diseases 2006;65(10):1390-3.
2006: Marta Boffito; Desmond Maitland; Laura Dickinson; David Back; Andrew Hill; Carl Fletcher; Graeme Moyle; Mark Nelson; Brian Gazzard; Anton Pozniak
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
AIDS research and human retroviruses 2006;22(8):749-56.
2006: Alan Winston; David Back; Carl Fletcher; Lesley Robinson; Jennifer Unsworth; Izabela Tolowinska; Malte Schutz; Anton L Pozniak; Brian Gazzard; Marta Boffito
Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers.
AIDS (London, England) 2006;20(10):1401-6.
2006: David Back; Sara Gibbons; Saye Khoo
An update on therapeutic drug monitoring for antiretroviral drugs.
Therapeutic drug monitoring 2006;28(3):468-73.
2006: Alan Winston; Nimesh Patel; David Back; Saye Khoo; Steve Bulbeck; Sundhiya Mandalia; Anton L Pozniak; Mark Nelson; Graeme Moyle; Brian Gazzard; Marta Boffito
Different methods to calculate the inhibitory quotient of boosted single protease inhibitors and their association with virological response.
Journal of acquired immune deficiency syndromes (1999) 2006;41(5):675-6.
2005: Laura Dickinson; Lesley Robinson; John F Tjia; Saye Khoo; David Back
Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;829(1-2):82-90.
2005: Saye Khoo; David Back; Peter Winstanley
The potential for interactions between antimalarial and antiretroviral drugs.
AIDS (London, England) 2005;19(10):995-1005.
2005: Marta Boffito; Desmond Maitland; Laura Dickinson; David Back; Andrew Hill; Carl Fletcher; Graeme Moyle; Mark Nelson; Brian Gazzard; Anton Pozniak
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.
The Journal of antimicrobial chemotherapy 2005;55(4):542-5.
2005: Samantha L Hider; Patrick G Hoggard; Saye Khoo; David Back; Ian N Bruce
Drug efflux transporters in rheumatoid arthritis: comment on the article by Kremer.
Arthritis and rheumatism 2005;52(2):670; author reply 672.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs.
Antiviral therapy 2005;10(4):469-77.
2005: Marta Boffito; Edward Acosta; David Burger; Courtney V Fletcher; Charles Flexner; Rodolphe Garaffo; Giorgio Gatti; Michael Kurowski; Carlo Federico Perno; Gilles Peytavin; Mario Regazzi; David Back
Current status and future prospects of therapeutic drug monitoring and applied clinical pharmacology in antiretroviral therapy.
Antiviral therapy 2005;10(3):375-92.
2005: Marta Boffito; David Back; Meredith Stainsby-Tron; Andrew Hill; Giovanni Di Perri; Graeme Moyle; Mark Nelson; Jaqui Tomkins; Brian Gazzard; Anton Pozniak
Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.
British journal of clinical pharmacology 2005;59(1):38-42.
2004: Bridget Maher; Judy Lloyd; Edmund G L Wilkins; William D Fraser; David Back; B Kevin Park; Munir Pirmohamed
Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters.
Antiviral therapy 2004;9(6):879-87.
2004: Marta Boffito; Laura Dickinson; Andrew Hill; David Back; Graeme Moyle; Mark Nelson; Christopher Higgs; Carl Fletcher; Brian Gazzard; Anton Pozniak
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2004;37(3):1376-84.
2004: Jennifer Ford; Marta Boffito; Adrian Wildfire; Andrew Hill; David Back; Saye Khoo; Mark Nelson; Graeme Moyle; Brian Gazzard; Anton Pozniak
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
Antimicrobial agents and chemotherapy 2004;48(7):2388-93.
2004: Marta Boffito; Laura Dickinson; Andrew Hill; David Back; Graeme Moyle; Mark Nelson; Christopher Higgs; Carl Fletcher; Sundhiya Mandalia; Brian Gazzard; Anton Pozniak
Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.
Antiviral therapy 2004;9(3):423-9.
2004: Alan Winston; Anton Pozniak; Nicola Smith; Carl Fletcher; Sundhiya Mandalia; Darmishta Parmar; Sarah Gibbons; David Back; Brian Gazzard; Mark Nelson
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?
AIDS (London, England) 2004;18(3):572-4.
2004: Martina Hennessy; Susan Clarke; J Paul Spiers; Dermot Kelleher; Fiona Mulcahy; Patrick G Hoggard; David Back; Michael Barry
Intracellular accumulation of nelfinavir and its relationship to P-glycoprotein expression and function in HIV-infected patients.
Antiviral therapy 2004;9(1):115-22.
2003: Andrew Owen; Ruben C Hartkoorn; Saye Khoo; David Back
Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines.
AIDS (London, England) 2003;17(15):2276-8.
2003: David Back; Sara Gibbons; Saye Khoo
Pharmacokinetic drug interactions with nevirapine.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S8-14.
2003: Becky Chandler; Lisa Almond; Jennifer Ford; Andrew Owen; Patrick G Hoggard; Saye Khoo; David Back
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro.
Journal of acquired immune deficiency syndromes (1999) 2003;33(5):551-6.
2003: Martina Hennessy; Susan Clarke; J Paul Spiers; Fiona Mulcahy; Dermot Kelleher; Emma Meadon; Bridget Maher; Colm Bergin; Saye Khoo; John F Tjia; Patrick G Hoggard; David Back; Michael Barry
Intracellular indinavir pharmacokinetics in HIV-infected patients: comparison with plasma pharmacokinetics.
Antiviral therapy 2003;8(3):191-8.
2003: Andrew Owen; Becky Chandler; Jenny Ford; Saye Khoo; David Back
Differential expression of human immunodeficiency virus coreceptors, by CEM, CEMVBL, and CEM E1000 cells.
The Journal of infectious diseases 2003;187(5):874-5; author reply 875-6.
2002: David Back; Giorgio Gatti; Carl Fletcher; Rodolphe Garaffo; Richard Haubrich; Richard Hoetelmans; Michael Kurowski; Andrew Luber; Concepta Merry; Carlo Federico Perno
Therapeutic drug monitoring in HIV infection: current status and future directions.
AIDS (London, England) 2002;16 Suppl 1():S5-37.
2002: David Back; Saye Khoo; Sara Gibbons
Therapeutic drug monitoring.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2002;1(3):84-5.
2002: Martina Hennessy; Dermot Kelleher; J Paul Spiers; Michael Barry; P Kavanagh; David Back; Fiona Mulcahy; John Feely
St Johns wort increases expression of P-glycoprotein: implications for drug interactions.
British journal of clinical pharmacology 2002;53(1):75-82.
1999: M Barry; S Clarke; Fiona Mulcahy; David Back
Hydroxyurea-induced neurotoxicity in HIV disease.
AIDS (London, England) 1999;13(12):1592-4.
1999: Michael Barry; Fiona Mulcahy; Concepta Merry; S Gibbons; David Back
Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
Clinical pharmacokinetics 1999;36(4):289-304.
1998: Fiona Mulcahy; M Barry; Concepta Merry; David Back
Nelfinavir and nevirapine interaction?
AIDS (London, England) 1998;12(17):2361.
1997: M Barry; S Gibbons; David Back; Fiona Mulcahy
Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.
Clinical pharmacokinetics 1997;32(3):194-209.
1997: Concepta Merry; Fiona Mulcahy; M Barry; S Gibbons; David Back
Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
AIDS (London, England) 1997;11(2):268-9.
1996: Concepta Merry; M Barry; S Gibbons; Fiona Mulcahy; David Back
Improved tolerability of ritonavir derived from pharmacokinetic principles.
British journal of clinical pharmacology 1996;42(6):787.
1995: Diana M Gibb; M Barry; S Ormesher; L Nokes; M Seefried; Carlo Giaquinto; David Back
Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection.
British journal of clinical pharmacology 1995;39(5):527-30.
1994: M Barry; M Wild; G Veal; David Back; A Breckenridge; R Fox; N Beeching; F Nye; P Carey; D Timmins
Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers.
AIDS (London, England) 1994;8(8):F1-5.
1993: M Barry; David Back; S Ormesher; N Beeching; F Nye
Metabolism of didanosine (ddI) by erythrocytes: pharmacokinetic implications.
British journal of clinical pharmacology 1993;36(1):87-8.
1993: M Barry; J Howe; David Back; A Breckenridge; R Brettle; R Mitchell; N J Beeching; F J Nye
The effects of indomethacin and naproxen on zidovudine pharmacokinetics.
British journal of clinical pharmacology 1993;36(1):82-5.